可惜大资金持续不买账//@虾里巴人:回复@虾里巴人:$人福医药(SH600079)$ 旗下子公司的新冠疫苗研发进展美国合作伙伴GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program3.4号更新了新冠疫苗项目的进展，佐治亚州亚特兰大市，2020年3月4日——GeoVax实验室有限公司(OTC: GOVX)，一家开发人类免疫疗法和针对传染病和癌症的疫苗的生物技术公司，今天提供了其用于预防/控制由非典冠状病毒引起的新型冠状病毒疾病(COVID-19)的疫苗开发的最新情况。GeoVax的首席科学官Farshad Guirakhoo博士在加利福尼亚州圣地亚哥举行的世界免疫治疗大会上发表题为“利用新型MVA平台开发针对新发传染病的单剂量疫苗”的演讲时，介绍了最新情况。 GeoVax正在利用其GV-MVA-VLPTM疫苗平台和专业知识，利用源于中国武汉的COVID-19病毒的基因序列设计和构建候选疫苗。1月下旬，该公司签署了一份意向书，开始与中国武汉的疫苗开发商BravoVax合作，共同开发一种疫苗。根据这一安排，在收到GeoVax的候选疫苗后，BravoVax将提供测试和生产支持，以及与中国公共卫生和监管机构的直接互动。 Guirakhoo博士指出，“开发一种安全有效的疫苗来阻止当前和未来的COVID-19流行病是我们的高度优先事项。我们已经设计了许多候选疫苗，根据它们的安全性、免疫原性和保护效力，通过适当的动物试验研究将这些候选疫苗的范围缩小。最终的候选药物将被选择用于生产和初步的人类临床试验，以确定其安全性和免疫原性。我们与BravoVax的前期工作正在卓有成效地进行，对测试计划进行了持续的交叉贡献，并与资助机构进行了相应的对话。此外，GeoVax正致力于开发一种专利疫苗开发流程改进，旨在显著加快疫苗开发流程，实现测试和验证。” 吉拉胡博士继续说道，“也许至关重要的是，我们的疫苗载体(MVA)的病毒基础已经有50多年的安全记录，并且最近已经被美国食品和药物管理局批准用于预防天花和猴痘疾病。因此，我们期望我们的COVID-19疫苗比其他未经证实的技术获得更快的监管许可。” GeoVax公司总裁兼首席执行官大卫·多德评论道:“当前的COVID-19疫情凸显了识别和验证疫苗开发平台的至关重要性，该平台能够为新的、紧急的传染性威胁提供快速疫苗响应。GeoVax GV-MVA-VLPTM平台此前已在针对各种传染性挑战(埃博拉、马尔堡、兹卡、艾滋病毒等)的动物研究中得到展示。)成为解决此类“疾病X”流行病威胁的优秀候选平台。我们期待着与我们的行业合作伙伴、政府机构和其他组织密切合作，将我们的开发(包括我们的COVID-19疫苗)推向关键的验证里程碑。”
Update Given During Presentation at the World Immunotherapy Congress
ATLANTA, GA, March 4, 2020 – GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. The update was given by GeoVax’s Chief Scientific Officer, Farshad Guirakhoo, PhD, during his presentation on emerging infectious diseases entitled “Development of Single-Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform” at the World Immunotherapy Congress in San Diego, California.
GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China. In late January, the Company entered into a letter of intent to begin a collaboration with BravoVax, a vaccine developer in Wuhan, China, to jointly develop a vaccine. Under the arrangement, upon receipt of vaccine candidates from GeoVax, BravoVax will provide testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities.
Dr. Guirakhoo stated, “Development of a safe and effective vaccine to stem current and future epidemics of COVID-19 is a high priority for us. We have designed a number of vaccine candidates which will be narrowed through appropriate animal testing studies based on their safety, immunogenicity and protective efficacy. The final candidate will then be selected for manufacturing and initial human clinical testing for safety and immunogenicity. Our preliminary work with BravoVax is proceeding productively, with ongoing cross-contributions to the testing plans and respective dialogue with funding agencies. In addition, GeoVax is working to develop a proprietary, patented vaccine development process improvement, intended to significantly speed-up the vaccine development process towards testing and validation.”
Dr. Guirakhoo continued, “Perhaps of critical importance is that the viral basis of our vaccine vector (MVA) has more than 50 years of safety records and has been recently approved by the FDA for prevention of smallpox and monkeypox diseases. We, therefore, expect faster regulatory licensure for our COVID-19 vaccine than for other, unproven technologies.”
David Dodd, GeoVax’s President and CEO, commented, “The current COVID-19 outbreak underscores the critical importance to identify and validate vaccine development platforms that can provide rapid vaccine response to new, emergent infectious threats. The GeoVax GV-MVA-VLPTM platform has been previously demonstrated in animal studies against a variety of infectious challenges (Ebola, Marburg, Zika, HIV, etc.) to be an excellent candidate platform for addressing such ‘Disease X’ epidemic threats. We look forward to working closely with our industry partners, government agencies and other organizations to advance our developments, including our COVID-19 vaccine, to critical validation milestones.”